Craft

Novacyt

Stock Price

€0.6

2024-10-29

Market Capitalization

€45.3 M

2024-10-29

Revenue

£11.6 M

FY, 2023

Novacyt Summary

Company Summary

Overview
Novacyt Group, an international specialist in cancer and infectious diseases, has diversified sales from diagnostic products used in LBC, oncology, microbiology, haematology and serology testing. We support a large global customer base which includes hospitals to large corporates. Our proprietary technology platform NOVAPREP® is a unique next generation liquid based cytology solution focused on cancer management.
Type
Public
Status
Active
HQ
Vélizy-Villacoublay, FR | view all locations
Website
http://novacyt.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • James Wakefield

    James Wakefield, Non-executive Director and Chairman of the Board

  • James McCarthy

    James McCarthy, Group Chief Financial Officer

  • David Allmond

    David Allmond, Chief Executive Officer

  • Paul Oladimeji

    Paul Oladimeji, Group Head of R&D

    LocationsView all

    3 locations detected

    • Vélizy-Villacoublay, Île-de-France HQ

      France

      13 Avenue Morane Saulnier

    • Camberley, England

      United Kingdom

      1, Watchmoor Point

    • Chandler's Ford, England

      United Kingdom

      York House, School Lane,, School Ln

    Novacyt Financials

    Summary Financials

    Revenue (H1, 2024)
    £10.3M
    Gross profit (H1, 2024)
    £5.7M
    Net income (H1, 2024)
    (£17.7M)
    Cash (H1, 2024)
    £32.9M
    EBIT (H1, 2024)
    (£17.1M)
    Enterprise value
    $25.5M

    Footer menu